

**Marshall
& Melhorn**

Telephone No. (419) 249-7100 Fax No. (419) 249-7151
Four SeaGate, Eighth Floor, Toledo, Ohio 43601

Fax Transmission

RECEIVED
CENTRAL FAX CENTER
JAN 03 2005

TO: U.S. Patent and Trademark Office
ATTN: M. Thompson, Examiner
FAX #: 703 872 9306
FROM: D. Edward Dolgorukov
DATE: January 3, 2005
OPERATOR: Lisa Donbrosky

We are transmitting a total of 3 pages (including this cover sheet). If transmission is not complete, please call (419) 249-7164.

COMMENTS:

Please see the attached Duplicate Supplemental Amendment re: Serial No. 09/363,234; filed July 27, 1999.

L2073-15369001

This message is intended for use only by the individual to whom it is addressed and may contain confidential and/or privileged information. If you are not the intended recipient, please take note that any dissemination, distribution or copying is not permitted. If you have received this communication in error, please destroy the original and notify us immediately by telephone so that we might prevent any recurrence. Thank you for your assistance.

I hereby certify that this correspondence is being transmitted
via facsimile to the Commissioner for Patents, at 703-872-
9306, on January 3, 2005

D. Edward Dolgorukov

(signature)

RECEIVED
CENTRAL FAX CENTER
JAN 03 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
DOUGLAS E. OTT, et al.)	Group Art Unit 3763
Serial No. 09/363,234)	Examiner: M.M. Thompson
Filed: July 27, 1999)	
For: METHOD AND APPARATUS)	Attorney Docket 1-15369
FOR TREATING GAS FOR)	Paper No.
DELIVERY TO AN ANIMAL)	

January 3, 2005

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

DUPLICATE SUPPLEMENTAL AMENDMENT

Honorable Sir:

Applicants filed an Amendment in the present application on December 2, 2004. In an Office Action dated November 4, 2004, the Examiner held that: "the reply filed on July 20, 2004 is not fully responsive to the prior Office Action because of the following omissions or matters: the reply must present arguments pointing out the specific distinctions believed to render the claims, including any newly presented claims patentable over any applied references. Claim 106 should be addressed." Claims 34-106 were pending at the time of the November 4, 2004 Office Action, and remain pending.

In response to the Office Action of November 4, 2004, applicants restated all arguments concerning allowability of the claims as if fully incorporated herein. In

1-15369

addition, applicants stated that Claim 106 is allowable at least because it requires a liquid phase pharmacologic agent, and the Examiner has not shown this in the prior art of record.


On December 6, 2004, applicants received a further Office action in the present application dated December 2, 2004. Upon examination, the Office Action of December 2, 2004 appeared to be a duplication of the Office Action of November 4, 2004.

Attempts to reach the Examiner to confirm this and to withdraw the duplicate action have been unsuccessful.

Therefore, to avoid possible abandonment of this application, this duplicate Supplemental Amendment is being filed with the following statement:

In response to the Office Action of December 2, 2004, applicants restate all arguments concerning allowability of the claims as if fully incorporated herein. In addition, applicants state that Claim 106 is allowable at least because it requires a liquid phase pharmacologic agent, and the Examiner has not shown this in the prior art of record.

Respectfully submitted,


D. Edward Dolgorukov
Registration No. 26,266

ATTORNEYS
MARSHALL & MELHORN, LLC
Four SeaGate, Eighth Floor
Toledo, Ohio 43604
(419) 249-7100
(419) 249-7151 (Facsimile)
Dolgorukov@marshall-melhorn.com